ATRA - Atara Biotherapeutics Inc Stock Price, Fair Value and News

$10.68-0.31 (-2.82%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ATRA Price Action

Last 7 days

-25.1%

Last 30 days

15.2%

Last 90 days

50%

Trailing 12 Months

-15.4%

ATRA RSI Chart

ATRA Valuation

Market Cap

61.5M

Price/Earnings (Trailing)

-0.46

Price/Sales (Trailing)

1.05

EV/EBITDA

-0.12

Price/Free Cashflow

-0.65

ATRA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ATRA Fundamentals

ATRA Revenue

Revenue (TTM)

63.6M

Rev. Growth (Yr)

1.8K%

Rev. Growth (Qtr)

40.33%

ATRA Earnings

Earnings (TTM)

-133.2M

Earnings Growth (Yr)

68.61%

Earnings Growth (Qtr)

-15.01%

ATRA Profitability

EBT Margin

-209.43%

Return on Equity

147.07%

Return on Assets

-93.31%

Free Cashflow Yield

-154.2%

ATRA Investor Care

Shares Dilution (1Y)

41.28%

Diluted EPS (TTM)

-25.7

ATRA Alerts

CITADEL ADVISORS LLC reported owning 4.6% of ATRA [2024-11-14]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	24.1M	71.8M	70.9M	63.6M
2021	4.2M	8.0M	13.2M	20.3M
2015	272.0K	412.0K	762.0K	0
2014	40.3K	68.5K	96.8K	125.0K
2013	0	0	0	12.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

CEO	Dr. Pascal Touchon D.V.M.
WEBSITE	atarabio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	317

Atara Biotherapeutics Inc Frequently Asked Questions

What is the ticker symbol for Atara Biotherapeutics Inc? What does ATRA stand for in stocks?

ATRA is the stock ticker symbol of Atara Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Atara Biotherapeutics Inc (ATRA)?

As of Wed Nov 20 2024, market cap of Atara Biotherapeutics Inc is 61.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATRA stock?

You can check ATRA's fair value in chart for subscribers.

Is Atara Biotherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ATRA is over valued or under valued. Whether Atara Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Atara Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATRA.

What is Atara Biotherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Nov 20 2024, ATRA's PE ratio (Price to Earnings) is -0.46 and Price to Sales (PS) ratio is 1.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATRA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Atara Biotherapeutics Inc's stock?

In the past 10 years, Atara Biotherapeutics Inc has provided -0.339 (multiply by 100 for percentage) rate of return.